S&P 500 Futures
(-0.01%) 5 307.50 points
Dow J Futures
(0.04%) 40 160 points
Nasdaq Futures
(-0.01%) 18 502 points
Oil
(1.72%) $82.75
Gas
(0.64%) $1.729
Gold
(0.78%) $2 230.00
Silver
(-0.14%) $24.72
Platinum
(0.38%) $913.20
USD/EUR
(0.33%) $0.926
USD/NOK
(0.58%) $10.83
USD/GBP
(0.09%) $0.792
USD/RUB
(-0.03%) $92.41

Realtime updates for Rigel Pharmaceuticals Inc [RIGL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
33.33%
return 0.32%
SELL
50.00%
return 1.49%
Last Updated27 Mar 2024 @ 16:00

4.93% $ 1.490

SELL 61808 min ago

@ $1.160

Issued: 14 Feb 2024 @ 09:35


Return: 28.45%


Previous signal: Feb 13 - 09:30


Previous signal: Buy


Return: 0.00 %

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...

Stats
Today's Volume 656 330
Average Volume 1.12M
Market Cap 261.31M
EPS $0 ( 2024-03-05 )
Next earnings date ( $-0.0300 ) 2024-05-07
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -10.64
ATR14 $0.00300 (0.20%)
Insider Trading
Date Person Action Amount type
2024-02-28 Schorno Dean L Buy 78 500 Employee Stock Option (right to buy)
2024-02-28 Schorno Dean L Buy 62 500 Employee Stock Option (right to buy)
2024-02-28 Santos David A Buy 80 000 Employee Stock Option (right to buy)
2024-02-28 Santos David A Buy 78 500 Employee Stock Option (right to buy)
2024-02-28 Rodriguez Raul R Buy 300 000 Employee Stock Option (right to buy)
INSIDER POWER
92.88
Last 99 transactions
Buy: 9 521 500 | Sell: 304 047

Volume Correlation

Long: -0.39 (neutral)
Short: 0.63 (weak)
Signal:(48.027) Neutral

Rigel Pharmaceuticals Inc Correlation

10 Most Positive Correlations
CRNC0.963
ROIV0.959
NLSP0.958
MLCO0.954
MOMO0.954
FXCO0.951
CTSO0.949
APAC0.948
VRDN0.946
BRAC0.945
10 Most Negative Correlations
GRIN-0.954
PIII-0.939
RIVN-0.938
SNPX-0.925
OP-0.924
SWAV-0.923
ZENV-0.923
LAWS-0.919
NAKD-0.916
ENPH-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rigel Pharmaceuticals Inc Correlation - Currency/Commodity

The country flag 0.00
( neutral )
The country flag 0.04
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.41
( neutral )

Rigel Pharmaceuticals Inc Financials

Annual 2023
Revenue: $116.88M
Gross Profit: $109.77M (93.92 %)
EPS: $-0.140
Q4 2023
Revenue: $35.79M
Gross Profit: $32.00M (89.41 %)
EPS: $0.00420
Q3 2023
Revenue: $28.13M
Gross Profit: $26.87M (95.49 %)
EPS: $-0.0326
Q2 2023
Revenue: $26.89M
Gross Profit: $25.81M (96.00 %)
EPS: $-0.0380

Financial Reports:

No articles found.

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators